Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma
Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma
To assess the effect of IMRT using VMAT rapidarc approach, followed by adjuvant temozolomide
 on survival and quality of life in elderly, poor performance status patients with newly
 diagnosed HGG.
Investigators designed this study with the aim to assess the effect of IMRT using VMAT
 rapidarc approach, followed by adjuvant temozolomide on survival and quality of life in
 elderly, poor performance status patients with newly diagnosed HGG. The potential advantage
 of this approach is deliver a more selective irradiation to tumor's target with reducing the
 dose to normal brain and to allow the delivery of a higher dose, optimizing the therapeutic
 window.
Inclusion Criteria:

 -  Patients aged ≥ 70 years

 -  Karnosky performance status (KPS) ≤60

 -  Histologically confirmed HGG after tumor biopsy

 -  GBM

 -  Anaplastic Astrocytoma

 -  Anaplastic Oligoastrocytoma

 -  Anaplastic Oligodendroglioma without IDH1 mutation and no codeletion 1p19q

 -  Estimated survival ≥ 3 months.

 -  Normal liver, Kidney and bone marrow function

 -  Written informed consent

 Exclusion criteria:

 -  Prior radiation therapy

 -  Other primary cancer

 Exclusion Criteria:

 -